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Generation of reactive oxygen species during dopamine (DA) oxidation could be one of the factors
leading to the selective loss of nigral dopaminergic neurons in Parkinson’s disease (PD). Vesicular
monoamine transporter type 2 (VMAT2) proteins in nerve terminals uptake dopamine into synaptic
vesicles, preventing its cytoplasmic accumulation and toxic damage to nigral neurons. Polymorphisms in
VMAT2 gene and in its regulatory regions might therefore serve as genetic risk factors for PD. In the
present study, we have analyzed 8 single-nucleotide polymorphisms (SNPs) located within/around the
VMAT2 gene for association with PD in an Italian cohort composed of 704 PD patients and 678 healthy
controls. Among the 8 SNPs studied, only the 2 located within the promoter region (rs363371 and
rs363324) were signiﬁcantly associated with PD. In the dominant model, odds ratios were 0.72 (95%
conﬁdence interval [CI]: 0.6e0.9, p < 0.005) for rs363371 and 0.76 (95% CI: 0.6e0.9, p ¼ 0.01) for
rs363324; in the additive model, odds ratios were 0.78 (95% CI: 0.65e0.94, p ¼ 0.008) for rs363371 and
0.85 (95% CI: 0.7e20.92, p ¼ 0.04) for rs363324. There were no signiﬁcant relationships between the
remaining SNPs (rs363333, rs363399, rs363387, rs363343, rs4752045, and rs363236) and the risk of
sporadic PD in any genetic model. This study adds to the previous evidence suggesting that variability in
VMAT2 promoter region may confer a reduced risk of developing PD, presumably via mechanisms of gene
overexpression.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Parkinson’s disease (PD) is a debilitating neurologic disorder
characterized clinically by bradykinesia, resting tremor, rigidity,
and postural instability with a therapeutic response to levodopa.
Pathophysiologically, PD is characterized by the loss of dopamine
neurons in the substantia nigra (SN) pars compacta and by the
presence of intracellular inclusions known as Lewy bodies, which
are composed primarily of alpha-synuclein protein aggregates.
Although the disease etiology remains largely unclear, generation
of reactive oxygen species during oxidation of dopamine (DA) could
be one of the factors leading to the selective loss of nigral dopa-
minergic neurons in PD (Spina and Cohen, 1989).y, San Gerardo Hospital, Via
9 039 2339082; fax: þ39
ghina).
Y-NC-ND license.The vesicular monoamine transporter type 2 (VMAT2, SLC18A2)
uptakes cytosolic monoamines, including dopamine, into intracel-
lular secretory vesicles, preventing their toxicity in the cytosol and
discharging them into the extracellular space by exocytosis. Altered
function of VMAT2 proteins may therefore cause cytoplasmic
accumulation of free DA, leading to dopaminergic neuron death,
therefore being a risk factor for PD. VMAT2 is expressed in central,
peripheral, and enteric neurons as well as in platelets (Peter et al.,
1995). VMAT2-deﬁcient mouse exhibits increased oxidative stress,
progressive loss of DA terminals and cell bodies in the SN pars
compacta, alpha-synuclein accumulation (Caudle et al., 2007), and
increased sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine (MPTP) toxicity (Mooslehner et al., 2001); interestingly, this
model displays also motor and nonmotor symptoms of PD (Taylor
et al., 2011). In humans, the involvement of VMAT2 in PD patho-
genesis is supported by positron emission tomography studies
showing signiﬁcantly lower VMAT2 densities in the putamen,
caudate, and SN of PD patients (Bohnen et al., 2006; Lee et al., 2000;
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VMAT2 messenger RNA (mRNA) levels were observed in platelets
from patients (Sala et al., 2010).
Polymorphisms in the VMAT2 gene or in its regulatory regions
that affect its quantitative expression or protein function might
therefore represent genetic risk factors for PD. Some common gain-
of-function haplotypes in VMAT2 promoter have been reported to
confer a protective effect against PD in women (Glatt et al., 2006),
whereas no studies have so far addressed speciﬁcally the associa-
tion of intragenic VMAT2 variability with PD in Caucasian pop-
ulations. In light of these premises, we carried out an association
study to evaluate whether genetic variants in VMAT2 gene and in its
regulatory regionsmight inﬂuence either susceptibility to PD or age
of onset of the disease in a series of Italian sporadic PD patients and
unrelated healthy controls.
2. Methods
2.1. Subjects
The study included 704 PD patients recruited consecutively
from the outpatient clinic for movement disorders at the Depart-
ment of Neurology of San Gerardo Hospital in Monza and at the
Parkinson Institute in Milan. PD patients were diagnosed according
to the standard criteria (Gelb et al., 1999). Among patients, 45 (7.5%)
reported a family history of PD in at least a ﬁrst-degree or second-
degree relative. PD cases with an age at onset (AAO) of <40 years
were screened to exclude that they were carriers of recognized PD-
causing mutations (Parkin, PINK1, and LRRK2 genes); the remaining
familial cases were screened for the highly penetrant G0219S
mutation in the LRRK2 gene that was absent in all the examined
subjects. All the 45 cases with a family history of PD were included
in the analysis. Control population consisted of 678 individuals,
comprising healthy spouses and former blood donors. Both patients
and controls were Caucasians, and the controls were geographically
matched to the cases. None of the controls had clinical evidence of
neurologic disease (as assessed by neurologic examination) or
familial history of neurodegenerative diseases. None of the patients
and of the controls had a current or former history of alcohol use
disorders. Informed consent for participation was obtained from all
the subjects. Full ethical committee approval for this investigation
was obtained.
2.2. Markers selection and genotyping
The present analysis comprised a total of 8 single-nucleotide
polymorphisms (SNPs). SNPs were selected according to the inter-
marker distance, their minor allele frequency (MAF >5%), the Illu-
mina design scores (>0.7), and the previous publications showing
associations with other dopamine-related traits. In detail, theTable 1
Overview of location and type of the genotyped SNPs
SNP ID Genome position (base pair)a Allele 1
rs363371 118976386 G
rs363324 118979152 A
rs363333 118994085 T
rs363399 118998861 T
rs363387 119003564 T
rs363343 119004938 A
rs4752045 119009680 G
rs363236 119028361 T
Allele 1, major frequency allele and allele 2, minor frequency allele.
Key: MAF, minor allele frequency; SNPs, single-nucleotide polymorphisms; UTR, untran
a Base position according to National Center for Biotechnology Information genome b2 SNPs in the promoter region (rs363371 and rs363324) previously
identiﬁed by resequencing and included in haplotypes have been
shown to be associated with alcoholism (Lin et al., 2005), rs363333
and rs363387 have been previously shown to be associated with
substance dependence (Schwab et al., 2005), and rs363399 and
rs4752045 with depression (Christiansen et al., 2007). Lastly,
considering a possible role in VMAT2 mRNA stability, an additional
candidate SNP in the 30-untranslated region (rs363236) was also
selected. Table 1 highlights the genomic positions and the type of
the genotyped markers.
Genomic DNAwas extracted from peripheral venous blood using
a Qiagen Blood kit (Qiagen, Milan, Italy). SNPs were typed using the
VeraCode GoldenGate genotyping assay on Illumina BeadXpress
Reader Platform according to themanufacturer’s protocol (Illumina,
San Diego, CA, USA). The genotyping call rate for the studied SNPs
was >97%. Goodness of ﬁt of the genotype frequencies to Har-
dyeWeinberg (HW) expected proportions in control subjects was
examined.
2.3. Statistical analysis
Chi-square tests were used to compare sex distribution and
genotype frequencies between patients and controls and to test for
deviation from HW equilibrium. Student t test was used to assess
differences in age between the 2 groups. We used logistic regres-
sion analysis to test for the association between the VMAT2 gene
selected variants and PD risk. The estimated odds ratios (ORs) and
relative 95% conﬁdence intervals (CIs) were adjusted for sex, age at
enrollment, and smoking (ever/never). We performed analyses
assuming autosomal dominant, log-additive, and recessive models
of inheritance. In the test, all p values for individual SNPs, OR, and
95% CI are presented as noncorrected for multiple testing. Analyses
were performed for subjects overall and stratiﬁed by family history
of PD, age at study (divided in quartiles), and sex. The association of
each genetic variant with AAO of PD was assessed using Cox
proportional hazard models, adjusted for sex. For each genetic
variant, we calculated a hazard ratio, a 95% CI, and a 2-tailed p value.
All the analyses were performed using SPSS version 16. Power
calculations were carried out using the Quanto software version 1.2,
under a dominant model of inheritance. The pairwise linkage
disequilibrium (LD) between markers was estimated using Haplo-
view software (Barrett et al., 2005). The Ensembl genome browser
(http://www.ensembl.org/index.html) was used to identify and to
annotate nearby SNPs in LD (proxies) based on HapMap CEU.
Haplotype associations were explored using score tests (Schaid
et al., 2002) as implemented in the haplo.stats R Package (http://
mayoresearch.mayo.edu/mayo/research/schaid_lab/software.cfm).
The overall difference in haplotype frequencies between cases and
controls was assessed using a global score test. Haplotype-speciﬁc
tests were performed only including haplotypes with frequenciesAllele 2 MAF cases/controls Type of variant
A 0.19/0.23 Flanking 50 UTR
G 0.29/0.33 Flanking 50 UTR
C 0.09/0.10 Intron 2
C 0.22/0.24 Intron 2
G 0.07/0.08 Exon 2 synonymous
C 0.17/0.18 Intron 6
C 0.46/0.48 Intron 9
C 0.19/0.18 30 Downstream
slated region.
uild 36.
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the referent group in the regression analysis. Correction for
multiple testing was performed by applying the simulate¼TRUE
parameter in haplo.score that gives simulated p values based on
10,000 permutations.
3. Results
The demographic data for the 704 PD patients were as follows:
mean age at study was 65.14  9.3 years (range 32e90) and mean
AAO of symptoms was 57.28  10 years (range 27e87). There were
415 men and 289 women (maleefemale ratio 1.43:1). The 678
control subjects consisted of 375 men and 303 women; their mean
age at examination was 64.2  7.7 years (range 44e90). There was
no statistical difference in the age at study and sex between
patients and controls (p > 0.05).
The control genotype distributions were in agreement with the
HW equilibrium for all markers (HW p value > 0.05). The allele
frequencies of the examined polymorphisms showed close simi-
larity to HapMap CEU data. All the considered SNPs showed anMAF
more than 8%. LD between the studied SNPs was low as detailed in
Table 2. The LD statistics were similar in PD patients and controls.
Table 3 lists the estimated ORs and associated 95% CIs from the
association analysis between each SNP and PD, assuming autosomal
dominant and trend (additive) models of inheritance. Two out of
the 8 investigated SNPs, both located in the putative promoter
region at the 50 untranslated region, were inversely associated to PD
when assuming dominant (rs363371: OR 0.72, CI 0.62e0.97, p ¼
0.004; rs363324: OR 0.76, CI 0.61e0.95, p ¼ 0.01) and trend model
of inheritance (rs363371: OR 0.78, CI 0.65e0.94, p ¼ 0.008;
rs363324: OR 0.85, CI 0.72e0.92, p ¼ 0.04). After Bonferroni
correction for multiple comparisons, only rs363371 remained
signiﬁcantly associated with PD (corrected p value ¼ 0.03, domi-
nant model). Sensitivity analyses excluding patients with a family
history of PD yielded similar results.
The remaining intragenic SNPs were not signiﬁcantly associated
with PD overall or in strata deﬁned by age at study, sex, and family
history (data not shown).
Furthermore, we tested the possible association among all the
different combinations of alleles at the 8 polymorphic loci with PD.
Four common haplotypes (GATTTAGT, frequency in cases/
controls ¼ 0.30/0.29; GATTTACT, frequency ¼ 0.23/0.21; GATTTACC,
frequency ¼ 0.07/0.07; and AGTCTAGT, frequency ¼ 0.05/0.06) and
several rare ones (with frequency <5%) were inferred. None of the
common haplotypes was associated with the overall risk for PD
(global haplotype association p value ¼ 0.56). Given the observed
LD pattern between the studied SNPs (with poor linkage between
the 50 half and the 30 half markers), we then partitioned the whole
haplotype into smaller segments (composed of 2e4 adjacent
markers) and tested them for association with PD. Consistent with
the individual SNP analysis, a signiﬁcant association with PD wasTable 2
Pairwise linkage disequilibrium measurements between SNPs (r2 below and D0 above th
D0
SNP ID rs363371 rs363324 rs363333 rs
r2 rs363371 1 0.868 0.
rs363324 0.61 0.932 0.
rs363333 0.025 0.207 1
rs363399 0.878 0.535 0.035
rs363387 0.025 0.165 0.743 0.
rs363343 0.198 0.116 0.012 0.
rs4752045 0.001 0.005 0.007 0.
rs363236 0.002 0.001 0.001 0.
Key: SNPs, single-nucleotide polymorphisms.observed for the haplotype including the 2 promoter variants,
rs363371 and rs363324 (global p value¼ 0.04). In particular, the all-
minor allele haplotype AG (the second most frequent haplotype in
both case and control populations) was signiﬁcantly underrepre-
sented in cases (frequency 19%) as compared with controls
(frequency 23%), hence being associated with a reduced PD risk as
compared with the most frequent haplotype GA (OR 0.78, 95% CI
0.65e0.94, permutation-based p value ¼ 0.03, additive model).
Finally, in analyses restricted to PD cases, none of the studied
SNPs displayed a signiﬁcant association with age at disease onset
under additive or dominant models, either in the overall sample or
after stratiﬁcation by sex (data not shown).
4. Discussion
In our study, we found that 2 polymorphisms located in the
putative promoter region of the VMAT2 gene were inversely asso-
ciated to PD, whereas the other SNPs within the gene were not
related to the risk of developing PD or to disease AAO.
The human VMAT2 gene consists of 16 exons and 15 introns and
has been localized to chromosome 10q25. The recently launched
website PDGene (http://www.pdgene.org/), which systematically
reviews genetic association studies of PD including genome-wide
association studies (GWAS), conﬁrms that information regarding
the association of VMAT2 gene with PD is still deﬁcient. A single
caseecontrol study comprising 190 Japanese patients and 190
controls failed to identify any signiﬁcant association among 3
intronic SNPs in the gene (rs2072362, rs3523, and rs363334) and PD
(Mizuta et al., 2006). Although none of the SNPs analyzed in the
present studywas speciﬁcally tested in the publicly accessibleGWAS
(as assessed using the National Center for Biotechnology Informa-
tion database of genotypes and phenotypes, http://view.ncbi.nlm.
nih.gov/dbgap), the National Institute of Neurological Disorders
and Stroke (NINDS) Genome-Wide Genotyping in Parkinson’s
Disease (dbGaP study accession number: phs000089.v3.p2) and the
Center of Inherited Disease Research (CIDR): GWAS in Familial Par-
kinson Disease (phs000126.v1.p1) contained respectively 2
(rs363327 and rs1860404) and 1 (rs1860404) SNPs in high LD with
our variants rs363343 and rs363333, which similarly were not
associated with PD. Hence the present study, extending the analysis
to more SNPs inside the gene (both in coding and noncoding
regions), adds toprevious evidence showingno association between
intragenic VMAT2 variability and PD.
A few more studies focused on the association of variants in the
VMAT2 promoter region with PD. In stark contrast to the very low
degree of variability of the coding sequence, a high degree of
genetic variability in the VMAT2 promoter region has been identi-
ﬁed (Glatt et al., 2001, 2006). Lin et al. (2005) sequenced the 17.4-kb
VMAT2 promoter region in 23 Caucasian individuals and identiﬁed
47 polymorphisms conferring 13 haplotypes associated to dif-
ferent promoter activities, as suggested by in vitro luciferase-e diagonal) calculated using the control sample
363399 rs363387 rs363343 rs4752045 rs363236
965 1 0.52 0.005 0.011
91 0.963 0.506 0.096 0.028
0.989 0.709 0.236 0.036
1 0.565 0.038 0.021
026 0.818 0.235 0.06
22 0.012 0.005 0.112
0001 0.005 0.003 0.316
002 0.001 0.012 0.024
Table 3
Single-marker frequencies and association analyses with risk of PD
Genotype frequency, n (%)a Dominant model Trend model
1/1 1/2 2/2 OR (95% CI) p Value (pcorr value)b OR (95% CI) p Value
rs363371
Cases 464 (66) 208 (29.6) 31 (4.4) 0.72 (0.58e0.90) 0.004 (0.03) 0.78 (0.65e0.94) 0.0088 (0.07)
Controls 396 (58.5) 245 (36.2) 36 (5.3)
rs363324
Cases 364 (52.5) 259 (37.4) 70 (10.1) 0.76 (0.61e0.95) 0.01 (0.08) 0.85 (0.72e0.92) 0.04 (0.32)
Controls 304 (45.4) 291 (43.5) 74 (11.1)
rs363333
Cases 576 (81.9) 121 (17.2) 6 (0.9) 0.97 (0.74e1.28) 0.85 0.94 (0.73e1.21) 0.62
Controls 551 (81.3) 116 (17.1) 11 (1.6)
rs363399
Cases 435 (61.8) 229 (32.6) 39 (5.6) 0.83 (0.66e1.03) 0.086 0.91 (0.76e1.10) 0.34
Controls 387 (57.2) 260 (38.5) 29 (4.3)
rs363387
Cases 596 (85.8) 96 (13.8) 3 (0.4) 1.01 (0.74e1.37) 0.95 0.97 (0.73e1.28) 0.81
Controls 577 (85.5) 91 (13.5) 7 (1)
rs363343
Cases 481 (68.4) 203 (28.9) 19 (2.7) 1.01 (0.80e1.27) 0.94 0.97 (0.80e1.19) 0.78
Controls 463 (68.6) 187 (27.7) 25 (3.7)
rs4752045
Cases 210 (29.8) 335 (47.6) 159 (22.6) 0.85 (0.67e1.07) 0.17 0.92 (0.79e1.07) 0.27
Controls 181 (26.7) 339 (50) 158 (23.3)
rs363236
Cases 461 (66) 217 (31) 21 (3) 1.05 (0.84e1.32) 0.68 1.03 (0.85e1.25) 0.76
Controls 451 (66.9) 200 (29.7) 23 (3.4)
The estimated ORs and relative 95% CIs were adjusted for sex, age at enrollment, and smoking.
Key: PD, Parkinson’s disease; OR, odds ratio; CI, conﬁdence interval.
a Allele 1 (major frequency/wild-type allele) and allele 2 (minor frequency/variant allele) base type for each marker is speciﬁed in Table 1.
b p Value after Bonferroni correction for 8 single-nucleotide polymorphism tests (a ¼ 0.006). Signiﬁcant value is indicated in bold.
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(rs363371 and rs363324) genotyped in our study were among the
4 haplotype-deﬁning SNPs identiﬁed by Lin et al. (2005) and were
likely to be functional. The G allele (wild type) of rs363371 is
embedded in a consensus sequence for transcriptional repressor
GC-binding factor (GCF) that is expressed in many tissues, whereas
the minor A allele is not (Kageyama and Pastan, 1989). On the other
hand, rs363324 is in considerable LD with rs363371 (D0 ¼ 1, r2 ¼
0.61) and with another variant at the 50 untranslated
region, 2504T>C (rs2619096), which is probably a transcription
factor binding site, because the switching from T (wild-type allele)
to C (variant allele) could double the promoter activity in luciferase
assays in SHSY cells (Lin et al., 2005). Interestingly, regulatory
haplotypes including these variants have been associated also with
alcohol dependence, a different dopamine-related phenotype,
supporting the hypothesis that VMAT2 gene expression has in vivo
physiological relevance to dopamine homeostasis (Lin et al., 2005).
Another study screened the VMAT2 gene promoter region for
common haplotypes and tested their functional effects in reporter
gene assays, showing that only the gain-of-function haplotypes
(which displayed signiﬁcantly increased transcriptional activity
in vitro) were associated to a reduced risk of developing PD (Glatt
et al., 2006) in women. In a previous work, we analyzed the rela-
tionship between the 2 variants in the promoter region (rs363371
and rs363324) and VMAT2 mRNA levels in platelets from
a subgroup of the subjects genotyped for the present study, but we
failed to detect any association (Sala et al., 2010). Nevertheless,
because this was not the primary aim of that study, we were
probably underpowered to detect subtle differences in mRNA
platelet levels according to distinct genotypes/haplotypes;
furthermore, the in vitro data may not necessarily reﬂect the SNP
activity in vivo because of other unknown activities and known
mechanisms such as DNA methylation. Although the quantitative
effect of the variants in VMAT2 promoter region on transcriptional
activity is expected to be small, and it is unclear how our ﬁndingsmight relate to in vivo RNA and protein levels, the reported inverse
association might still be biologically meaningful: even slight
variations in VMAT2 expression might affect pathogenic mecha-
nisms involved in nigrostriatal degeneration (Chen et al., 2008) or
in the defense against PD-related environmental toxins (Lee et al.,
2000).
In contrast to Glatt’s and our ﬁndings, 2 polymorphic sequences
upstream the VMAT2 promoter region were not associated to PD in
the Japanese population (Kariya et al., 2005); however, the different
type (polymorphic microsatellites) and location of the studied
polymorphisms as well as the relevant ethnic differences previ-
ously observed in the genotype and allele frequencies of the poly-
morphisms in/around this gene (Crowley et al., 2008; Glatt et al.,
2006) may account for the discrepant ﬁndings. The aforemen-
tioned GWAS NINDS and CIDR examined only 2 variants
(rs10886051 and rs2532798) in the VMAT2 putative promoter
region, which were in high LD with rs363371 and rs363324,
respectively. Whereas in the NINDS study both variants were not
signiﬁcantly associated with PD (association p values ¼ 0.41 and
0.47, respectively), in the CIDR study only the SNP in LD with
rs363371 showed a tendency toward inverse association with PD
(OR ¼ 0.8, p ¼ 0.08), which is in favor of a possible involvement of
rs363371 rather than rs363324 in disease risk. Although our re-
ported associations of the promoter variants with PD may be
spurious, it is also recognized that efforts to minimize the false-
positive rates in GWAS may lead to missed associations. Replica-
tion of our ﬁndings in independent populations as well as marker
saturation of this still understudied VMAT2 regulatory regionwill be
required to determine if and how variability in VMAT2 promoter
affects susceptibility to PD.
Our study has some strengths. We adjusted our analyses for
possible confounders (sex, age at study, and smoking). The sample
size employed and the MAF for the selected SNPs provided sufﬁ-
cient statistical power for the main effect analyses. Assuming the
population susceptibility allele frequency to be the values observed
L. Brighina et al. / Neurobiology of Aging 34 (2013) 1712.e9e1712.e13 1712.e13in controls and a population prevalence of 0.02, our study had 80%
power (alpha¼ 0.05, uncorrected for multiple testing) to detect ORs
as small as 1.43 (or 0.71 or smaller) for the SNP with the highest
MAF and as small as 1.5 (or 0.63 or smaller) for the SNP with the
lowest MAF under a dominant model of inheritance. We also
considered multiple genetic models and stratiﬁed our sample for
multiple variables to explore possible effect modiﬁcations, in
particular by sex.
Although we planned our study to include most haplotype-
deﬁning SNPs based on the previous data from the literature, our
coverage of VMAT2 variability is inevitably incomplete, given the
low LD across and around the gene, as inferred from HapMap CEU
data; furthermore, nonsynonymous variants in coding regions of
the gene (most likely to alter its function), as well as rare poly-
morphisms (MAF <5%) and copy number variations, have been
excluded from our study. Hence, the possibility remains that
intragenic VMAT2 variability contributes to PD susceptibility or
interacts epistatically with other genes.
Another limitation of our study might be that, because we did
not conduct correction for multiple testing, false-positive ﬁndings
remain possible; hence, our results must be considered as prelim-
inary until replication in additional series is obtained. With use
of the Bonferroni criteria to adjust for multiple comparisons,
the association with PD of only 1 of the 2 SNPs in the promoter
(rs363371) remained signiﬁcant (corrected p value ¼ 0.03, domi-
nant model). However, the Bonferroni correction for multiple
testing takes no account of LD between adjacent variants, thus
leading to overcorrection and possible rejection of true-positive
ﬁndings (Attia et al., 2009).
In conclusion, the current study suggests that variability within
the VMAT2 promoter region may confer a reduced risk of devel-
oping PD. If conﬁrmed and supported by further functional studies,
genetic association of these variants with PD susceptibility might
also support molecular targeting of the VMAT2 gene or gene
products as a therapeutic strategy for the disease.
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